(19)
(11)EP 3 473 619 B8

(12)CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15)Correction information:
Corrected version no 1 (W1 B1)

(48)Corrigendum issued on:
04.11.2020 Bulletin 2020/45

(45)Mention of the grant of the patent:
09.09.2020 Bulletin 2020/37

(21)Application number: 18204389.3

(22)Date of filing:  06.11.2015
(51)International Patent Classification (IPC): 
C07D 401/14(2006.01)
A61P 35/00(2006.01)
A61K 31/4545(2006.01)

(54)

AURORA A KINASE INHIBITOR

AURORA-A-KINASE-INHIBITOR

INHIBITEUR DE KINASE AURORA A


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30)Priority: 14.11.2014 US 201462079742 P

(43)Date of publication of application:
24.04.2019 Bulletin 2019/17

(62)Application number of the earlier application in accordance with Art. 76 EPC:
15798602.7 / 3218366

(73)Proprietor: ELI LILLY AND COMPANY
Indianapolis, IN 46285 (US)

(72)Inventor:
  • Henry, James Robert
    Indianapolis, 46206-6288 (US)

(74)Representative: Smith, Andrew George 
Eli Lilly and Company Limited European Patent Operations Lilly Research Centre Erl Wood Manor
Windlesham, Surrey GU20 6PH
Windlesham, Surrey GU20 6PH (GB)


(56)References cited: : 
WO-A1-2009/104802
WO-A1-2013/129443
  
      
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).